Trial · NCT02815995
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
NCT02815995, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2025-06-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes. Trials, record NCT02815995. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02815995
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
- NCT number
- NCT02815995
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 57 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Advanced and/or Metastatic Sarcoma
- Interventions
- Durvalumab, Tremelimumab
- First posted
- 2016-06-28
- Last updated
- 2025-06-12
- Results first posted
- 2025-06-12
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) | 12 weeks | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20%increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
| Secondary | Tumor Response | 8 weeks, confirmatory scan at least 4 wks or later | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR),Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
| Secondary | Overall Survival (OS) | 44 months | OS defined as the time from treatment onset to death. OS estimated using the Kaplan-Meier method. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-Free Survival (PFS) | 12 weeks | proportion of participants | NUMBER | |
| SECONDARY | Tumor Response | 8 weeks, confirmatory scan at least 4 wks or later | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Survival (OS) | 44 months | months | MEDIAN |
Source ClinicalTrials.gov
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | Adipocytic Tumors Group | 0.17 | 95% Confidence Interval 0.01 to 0.52 | proportion of participants | |
| Progression-Free Survival (PFS) | Vascular Tumors Group | 0.3 | 95% Confidence Interval 0.07 to 0.58 | proportion of participants | |
| Progression-Free Survival (PFS) | Undifferentiated Pleomorphic Sarcoma Group | 0.4 | 95% Confidence Interval 0.05 to 0.75 | proportion of participants | |
| Progression-Free Survival (PFS) | Synovial Sarcoma Group | 0.8 | 95% Confidence Interval 0.2 to 0.97 | proportion of participants | |
| Progression-Free Survival (PFS) | Osteosarcoma Group | 0.2 | 95% Confidence Interval 0.01 to 0.58 | proportion of participants | |
| Progression-Free Survival (PFS) | Other Sarcomas Group | 0.45 | 95% Confidence Interval 0.17 to 0.71 | proportion of participants | |
| Progression-Free Survival (PFS) | Alveolar Soft-part Sarcoma Group | 0.9 | 95% Confidence Interval 0.47 to 0.99 | proportion of participants | |
| Progression-Free Survival (PFS) | Chordomas Group | 0.8 | 95% Confidence Interval 0.2 to 0.97 | proportion of participants | |
| Tumor Response | Adipocytic Tumors Group | Best Response irRC - N/A | 0 | Participants | |
| Tumor Response | Vascular Tumors Group | Best Response irRC - N/A | 0 | Participants |
1 to 10 of 96Source ClinicalTrials.gov
See all 96 results by groupParticipant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Adipocytic Tumors Group | 6 | |
| Overall Study | STARTED | Vascular Tumors Group | 10 | |
| Overall Study | STARTED | Undifferentiated Pleomorphic Sarcoma Group | 5 | |
| Overall Study | STARTED | Synovial Sarcoma Group | 5 | |
| Overall Study | STARTED | Osteosarcoma Group | 5 | |
| Overall Study | STARTED | Other Sarcomas Group | 11 | |
| Overall Study | STARTED | Alveolar Soft-part Sarcoma Group | 10 | |
| Overall Study | STARTED | Chordomas Group | 5 | |
| Overall Study | COMPLETED | Adipocytic Tumors Group | 2 | |
| Overall Study | COMPLETED | Vascular Tumors Group | 1 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events736
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Myositis | Musculoskeletal and connective tissue disorders | Adipocytic Tumors Group | 0 | 6 | |
| other | Myositis | Musculoskeletal and connective tissue disorders | Vascular Tumors Group | 0 | 10 | |
| other | Myositis | Musculoskeletal and connective tissue disorders | Undifferentiated Pleomorphic Sarcoma Group | 1 | 5 | |
| other | Myositis | Musculoskeletal and connective tissue disorders | Synovial Sarcoma Group | 0 | 5 | |
| other | Myositis | Musculoskeletal and connective tissue disorders | Osteosarcoma Group | 0 | 5 | |
| other | Myositis | Musculoskeletal and connective tissue disorders | Other Sarcomas Group | 0 | 11 | |
| other | Myositis | Musculoskeletal and connective tissue disorders | Alveolar Soft-part Sarcoma Group | 0 | 10 | |
| other | Myositis | Musculoskeletal and connective tissue disorders | Chordomas Group | 0 | 5 | |
| other | Pneumonitis | Respiratory, thoracic and mediastinal disorders | Adipocytic Tumors Group | 1 | 6 | |
| other | Pneumonitis | Respiratory, thoracic and mediastinal disorders | Vascular Tumors Group | 1 | 10 |
1 to 10 of 736Source ClinicalTrials.gov
See all 736 adverse eventsAdverse event totals24
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adipocytic Tumors Group | 4 | 6 |
| Total, all-cause mortality | Vascular Tumors Group | 8 | 10 |
| Total, all-cause mortality | Undifferentiated Pleomorphic Sarcoma Group | 5 | 5 |
| Total, all-cause mortality | Synovial Sarcoma Group | 4 | 5 |
| Total, all-cause mortality | Osteosarcoma Group | 5 | 5 |
| Total, all-cause mortality | Other Sarcomas Group | 10 | 11 |
| Total, all-cause mortality | Alveolar Soft-part Sarcoma Group | 2 | 10 |
| Total, all-cause mortality | Chordomas Group | 0 | 5 |
| Total, other adverse events | Adipocytic Tumors Group | 2 | 6 |
| Total, other adverse events | Vascular Tumors Group | 3 | 10 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35934010 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02815995
GET https://conductscience.org/api/trials/v1/NCT02815995/results?page=2